Biophysical properties of the clinical-stage antibody landscape
By T. Jain, Tingwan Sun, Stéphanie Durand, A. Hall, N. Houston, Juergen H. Nett, Beth Sharkey, Beata Bobrowicz, Isabelle Caffry, Yao Yu and 9 more. 2017
574 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Claire Marks
- Matthew I. J. Raybould
- Adam J. Riesselman
- Christopher Sander
- Charlotte M. Deane
- Jung-Eun Shin
- Aaron W. Kollasch
- Elana Simon
In Molecular Biology
- Debora Marks
- Christopher Sander
- Adam J. Riesselman
- Jung-Eun Shin
- A. Kruse
- Conor McMahon
- A. Manglik
- Elana Simon
In Radiology, Nuclear Medicine and Imaging
- Claire Marks
- Matthew I. J. Raybould
- Konrad Krawczyk
- Adam J. Riesselman
- Christopher Sander
- Charlotte M. Deane
- A. Teplyakov
- Jiye Shi
Citations in the corpus
- Protein design and variant prediction using autoregressive generative models (2021, background): “The designed library had more length diversity and a longer CDR3 median length (13) than the synthetic library (12) (Supplementary Fig.”
- Five computational developability guidelines for therapeutic antibody profiling (2019, methodology): “As a dataset of mAbs unlikely to suffer with developability issues, we used the variable domain heavy- and light-chain sequences of 137 clinical-stage antibody therapeutics (137 CSTs) (18).”
- Antibody Structure and Function: The Basis for Engineering Therapeutics (2019, methodology): “When applied to the experimentally characterized antibodies in the clinical stage [277], AggScore accurately identified aggregation-prone regions and predicted changes in aggregation behavior upon residue mutation.”